Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
European Society for Medical Oncology to hold a virtual meeting » 04:55
09/18/21
09/18
04:55
09/18/21
04:55
ABBV

AbbVie

$107.75 /

-0.33 (-0.31%)

, AYLA

Ayala Pharmaceuticals

$12.25 /

-0.01 (-0.08%)

, DCPH

Deciphera

$33.08 /

+1.45 (+4.58%)

, GMAB

Genmab

$43.10 /

+0.845 (+2.00%)

, LPTX

Leap Therapeutics

$2.65 /

+0.13 (+5.16%)

, ORIC

Oric Pharmaceuticals

$25.20 /

+0.99 (+4.09%)

, SYNH

Syneos Health

$94.34 /

+0.55 (+0.59%)

, BGNE

BeiGene

$403.60 /

+18.32 (+4.75%)

, BMY

Bristol-Myers

$61.32 /

+0.1 (+0.16%)

, BYSI

BeyondSpring

$23.00 /

+0.47 (+2.09%)

, CALA

Calithera Biosciences

$2.25 /

+0.2 (+9.76%)

, GILD

Gilead

$71.61 /

+0.34 (+0.48%)

, GH

Guardant Health

$132.01 /

+5.01 (+3.94%)

, LLY

Eli Lilly

$230.17 /

-0.78 (-0.34%)

, IPSEY

Ipsen

$23.92 /

-0.395 (-1.62%)

, EXAS

Exact Sciences

$108.29 /

+5.47 (+5.32%)

, IDYA

Ideaya Biosciences

$26.90 /

+0.9 (+3.46%)

, GSK

GlaxoSmithKline

$38.94 /

-0.16 (-0.41%)

, RHHBY

Roche

$46.07 /

-0.75 (-1.60%)

, REGN

Regeneron

$651.38 /

-2.3 (-0.35%)

, PFE

Pfizer

$43.89 /

-0.57 (-1.28%)

, TAK

Takeda Pharmaceutical

$17.16 /

-0.045 (-0.26%)

, TMO

Thermo Fisher

$596.98 /

+36.11 (+6.44%)

, TCRR

TCR2 Therapeutics

$10.00 /

-5.715 (-36.38%)

, VERU

Veru

$8.94 /

+0.17 (+1.94%)

, VBLT

VBL Therapeutics

$2.32 /

-0.035 (-1.49%)

, VTRS

Viatris

$13.57 /

-0.13 (-0.95%)

, NVS

Novartis

$83.49 /

-0.88 (-1.04%)

ESMO 2021 Virtual…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ABBV AbbVie
$107.75 /

-0.33 (-0.31%)

AYLA Ayala Pharmaceuticals
$12.25 /

-0.01 (-0.08%)

DCPH Deciphera
$33.08 /

+1.45 (+4.58%)

GMAB Genmab
$43.10 /

+0.845 (+2.00%)

LPTX Leap Therapeutics
$2.65 /

+0.13 (+5.16%)

ORIC Oric Pharmaceuticals
$25.20 /

+0.99 (+4.09%)

SYNH Syneos Health
$94.34 /

+0.55 (+0.59%)

BGNE BeiGene
$403.60 /

+18.32 (+4.75%)

BMY Bristol-Myers
$61.32 /

+0.1 (+0.16%)

BYSI BeyondSpring
$23.00 /

+0.47 (+2.09%)

CALA Calithera Biosciences
$2.25 /

+0.2 (+9.76%)

GILD Gilead
$71.61 /

+0.34 (+0.48%)

GH Guardant Health
$132.01 /

+5.01 (+3.94%)

LLY Eli Lilly
$230.17 /

-0.78 (-0.34%)

IPSEY Ipsen
$23.92 /

-0.395 (-1.62%)

EXAS Exact Sciences
$108.29 /

+5.47 (+5.32%)

IDYA Ideaya Biosciences
$26.90 /

+0.9 (+3.46%)

GSK GlaxoSmithKline
$38.94 /

-0.16 (-0.41%)

RHHBY Roche
$46.07 /

-0.75 (-1.60%)

REGN Regeneron
$651.38 /

-2.3 (-0.35%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

TAK Takeda Pharmaceutical
$17.16 /

-0.045 (-0.26%)

TMO Thermo Fisher
$596.98 /

+36.11 (+6.44%)

TCRR TCR2 Therapeutics
$10.00 /

-5.715 (-36.38%)

VERU Veru
$8.94 /

+0.17 (+1.94%)

VBLT VBL Therapeutics
$2.32 /

-0.035 (-1.49%)

VTRS Viatris
$13.57 /

-0.13 (-0.95%)

NVS Novartis
$83.49 /

-0.88 (-1.04%)

ABBV AbbVie
$107.75 /

-0.33 (-0.31%)

09/14/21 Barclays
Regenxbio price target raised to $82 from $79 at Barclays
09/13/21 Chardan
Regenxbio pact with AbbVie accelerates RGX-314 'value capture,' says Chardan
09/08/21 JPMorgan
AbbVie offers 'best risk/reward story in the group,' says JPMorgan
09/07/21 Morgan Stanley
Morgan Stanley cuts Vertex Pharmaceuticals to Underweight amid AbbVie overhang
AYLA Ayala Pharmaceuticals
$12.25 /

-0.01 (-0.08%)

07/13/21 Ladenburg
Ayala Pharmaceuticals initiated with Buy, $29 target at Ladenburg
07/13/21 Ladenburg
Ayala Pharmaceuticals initiated with a Buy at Ladenburg
12/07/20
Fly Intel: Top five analyst initiations
12/07/20 Roth Capital
Ayala Pharmaceuticals initiated with a Buy at Roth Capital
DCPH Deciphera
$33.08 /

+1.45 (+4.58%)

08/04/21 H.C. Wainwright
Deciphera price target lowered to $70 from $75 at H.C. Wainwright
05/05/21 Barclays
Deciphera price target lowered to $65 from $70 at Barclays
05/05/21 H.C. Wainwright
Deciphera price target lowered to $75 from $80 at H.C. Wainwright
05/05/21 Piper Sandler
Deciphera price target lowered to $60 from $75 at Piper Sandler
GMAB Genmab
$43.10 /

+0.845 (+2.00%)

09/16/21
Fly Intel: Top five analyst downgrades
09/16/21 Jefferies
Genmab downgraded to Hold from Buy at Jefferies
09/07/21
Fly Intel: Top five analyst downgrades
09/07/21 Morgan Stanley
Morgan Stanley cuts Genmab to Underweight amid high investor expectations
LPTX Leap Therapeutics
$2.65 /

+0.13 (+5.16%)

09/16/21 Piper Sandler
Leap data show 'very favorable early signal,' says Piper Sandler
09/13/21 Raymond James
Leap Therapeutics price target raised to $4 from $3 at Raymond James
09/13/21 Piper Sandler
Leap combo sees 'strong' early response rate, says Piper Sandler
06/03/21 Baird
Leap Therapeutics transferred with Outperform at Baird
ORIC Oric Pharmaceuticals
$25.20 /

+0.99 (+4.09%)

07/06/21 Citi
Oric Pharmaceuticals upgraded to Buy after tumor data at Citi
07/06/21 Citi
Oric Pharmaceuticals upgraded to Buy from Neutral at Citi
03/25/21 H.C. Wainwright
Oric Pharmaceuticals price target raised to $54 from $52 at H.C. Wainwright
01/25/21 Citi
Oric Pharmaceuticals downgraded to Neutral from Buy at Citi
SYNH Syneos Health
$94.34 /

+0.55 (+0.59%)

08/04/21 Credit Suisse
Syneos Health assumed with an Outperform at Credit Suisse
07/13/21 Barclays
Syneos Health price target raised to $102 from $90 at Barclays
06/02/21 Truist
Syneos Health price target raised to $104 from $88 at Truist
04/30/21 Mizuho
Syneos Health price target raised to $90 from $82 at Mizuho
BGNE BeiGene
$403.60 /

+18.32 (+4.75%)

06/14/21 SVB Leerink
BeiGene price target raised to $417 from $388 at SVB Leerink
03/16/21 HSBC
BeiGene price target raised to $385 from $296 at HSBC
03/08/21 China Renaissance
BeiGene initiated with a Buy at China Renaissance
03/04/21 Goldman Sachs
Five Prime acquisition 'a strategic positive' for Amgen, says Goldman Sachs
BMY Bristol-Myers
$61.32 /

+0.1 (+0.16%)

09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
07/27/21 Mizuho
Bristol-Myers deal a positive signal about BridgeBio's BBP-398, says Mizuho
07/26/21 Truist
Bristol-Myers assumed with a Buy at Truist
07/26/21 Truist
Bristol-Myers assumed with a Buy at Truist
BYSI BeyondSpring
$23.00 /

+0.47 (+2.09%)

09/08/21 Baird
BeyondSpring initiated with an Outperform at Baird
08/04/21 Evercore ISI
BeyondSpring price target raised to $95 from $30 at Evercore ISI
08/04/21 William Blair
BeyondSpring may have new standard of care in lung cancer, says William Blair
08/04/21 H.C. Wainwright
Wainwright upgrades BeyondSpring with $100 target on lung cancer data
CALA Calithera Biosciences
$2.25 /

+0.2 (+9.76%)

01/05/21 SVB Leerink
Calithera Biosciences downgraded to Market Perform at SVB Leerink
01/05/21 SVB Leerink
Calithera Biosciences downgraded to Market Perform from Outperform at SVB Leerink
01/05/21 Citi
Calithera Biosciences price target lowered to $5 from $10 at Citi
01/05/21 H.C. Wainwright
Calithera Biosciences price target lowered to $4 from $9.50 at H.C. Wainwright
GILD Gilead
$71.61 /

+0.34 (+0.48%)

09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
07/30/21 BMO Capital
Gilead price target raised to $72 from $67 at BMO Capital
07/30/21 RBC Capital
Gilead price target raised to $84 from $81 at RBC Capital
06/29/21 Jefferies
Gilead data should move Yescarta up to second line in DLBCL, says Jefferies
GH Guardant Health
$132.01 /

+5.01 (+3.94%)

08/09/21 Canaccord
Guardant Health price target lowered to $180 from $195 at Canaccord
06/21/21 Wells Fargo
Guardant Health price target raised to $160 from $145 at Wells Fargo
06/15/21
Fly Intel: Top five analyst initiations
06/15/21 Raymond James
Guardant Health initiated with a Market Perform at Raymond James
LLY Eli Lilly
$230.17 /

-0.78 (-0.34%)

09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
09/02/21 SVB Leerink
AbbVie price target lowered to $142 from $148 at SVB Leerink
08/30/21 Cowen
Eli Lilly price target raised to $300 from $250 at Cowen
08/30/21 Citi
Lexicon price target raised to $20 from $13 at Citi
IPSEY Ipsen
$23.92 /

-0.395 (-1.62%)

08/16/21 Morgan Stanley
Ipsen price target lowered to EUR 88 from EUR 92 at Morgan Stanley
08/03/21 Morgan Stanley
Ipsen price target raised to EUR 92 from EUR 85 at Morgan Stanley
08/02/21 Societe Generale
Ipsen price target raised to EUR 101 from EUR 90 at Societe Generale
07/30/21 Credit Suisse
Ipsen price target raised to EUR 90 from EUR 75 at Credit Suisse
EXAS Exact Sciences
$108.29 /

+5.47 (+5.32%)

09/16/21 Canaccord
Exact Sciences salesforce expansion a net positive, says Canaccord
09/15/21 Raymond James
Exact Sciences' 'opportunistic' hires should boost sales, says Raymond James
09/15/21 Canaccord
Exact Sciences progress in MRD space a positive, says Canaccord
09/01/21 Baird
UnitedHealth update to CRC screening coverage not a surprise, says Baird
IDYA Ideaya Biosciences
$26.90 /

+0.9 (+3.46%)

06/03/21 Baird
Ideaya Biosciences assumed with an Outperform at Baird
04/22/21 Roth Capital
Ideaya Biosciences price target raised to $38 from $31 at Roth Capital
04/19/21 H.C. Wainwright
Ideaya Biosciences price target raised to $35 from $29 at H.C. Wainwright
04/16/21 Roth Capital
Ideaya Biosciences price target raised to $31 from $23 at Roth Capital
GSK GlaxoSmithKline
$38.94 /

-0.16 (-0.41%)

09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
08/26/21 UBS
GlaxoSmithKline price target raised to 1,540 GBp from 1,485 GBp at UBS
08/20/21 JPMorgan
GlaxoSmithKline price target raised to 1,500 GBp from 1,300 GBp at JPMorgan
08/19/21 Berenberg
GlaxoSmithKline price target raised to 1,625 GBp from 1,570 GBp at Berenberg
RHHBY Roche
$46.07 /

-0.75 (-1.60%)

09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
09/07/21 UBS
Roche price target raised to CHF 350 from CHF 345 at UBS
08/02/21 JPMorgan
Roche price target raised to CHF 360 from CHF 310 at JPMorgan
07/27/21 Societe Generale
Roche price target raised to CHF 353 from CHF 340 at Societe Generale
REGN Regeneron
$651.38 /

-2.3 (-0.35%)

09/15/21 Cantor Fitzgerald
Regeneron price target raised to $700 from $670 at Cantor Fitzgerald
09/15/21 H.C. Wainwright
Regeneron price target raised to $831 from $787 at H.C. Wainwright
09/15/21 Piper Sandler
Regeneron price target raised to $690 from $675 at Piper Sandler
09/09/21
Fly Intel: Top five analyst initiations
PFE Pfizer
$43.89 /

-0.57 (-1.28%)

09/17/21 Evercore ISI
Evercore ISI doesn't think FDA panel will recommend COVID-19 boosters
09/16/21 Canaccord
Exact Sciences salesforce expansion a net positive, says Canaccord
09/16/21 BofA
Moderna boosters already reflected in 'bullish' consensus, says BofA
09/15/21 Raymond James
Exact Sciences' 'opportunistic' hires should boost sales, says Raymond James
TAK Takeda Pharmaceutical
$17.16 /

-0.045 (-0.26%)

08/03/21 Piper Sandler
Arcturus strength attributable to large pharma's interest in mRNA, says Piper
04/27/21 Chardan
LogicBio collaborations may signal recognition of platforms, says Chardan
04/19/21 JPMorgan
Takeda Pharmaceutical downgraded to Neutral on R&D investments at JPMorgan
04/19/21 JPMorgan
Takeda Pharmaceutical downgraded to Neutral from Overweight at JPMorgan
TMO Thermo Fisher
$596.98 /

+36.11 (+6.44%)

08/04/21 Credit Suisse
Thermo Fisher assumed with an Outperform at Credit Suisse
08/04/21 Argus
Thermo Fisher price target raised to $600 from $530 at Argus
07/29/21 Cowen
Thermo Fisher price target raised to $560 from $525 at Cowen
07/29/21 BTIG
Thermo Fisher price target raised to $610 from $590 at BTIG
TCRR TCR2 Therapeutics
$10.00 /

-5.715 (-36.38%)

09/17/21 Wedbush
TCR2 Therapeutics downgraded to Neutral from Outperform at Wedbush
08/06/21 BMO Capital
TCR2 Therapeutics price target lowered to $44 from $53 at BMO Capital
06/24/21 Goldman Sachs
TCR2 Therapeutics initiated with a Buy at Goldman Sachs
06/11/21 BMO Capital
TCR2 Therapeutics coverage transferred at BMO Capital
VERU Veru
$8.94 /

+0.17 (+1.94%)

04/13/21 Jefferies
Veru initiated with a Buy at Jefferies
02/11/21 Oppenheimer
Veru price target raised to $24 from $19 at Oppenheimer
02/11/21 H.C. Wainwright
Veru price target raised to $22 from $17 at H.C. Wainwright
02/09/21 H.C. Wainwright
Veru price target raised to $17 from $12 at H.C. Wainwright
VBLT VBL Therapeutics
$2.32 /

-0.035 (-1.49%)

08/30/21 Roth Capital
Roth bullish on VBL Therapeutics as U.S. Phase 3 OVAL trial enrollment resumes
06/15/21 Roth Capital
Roth does not see material change to VBL readout timelines
06/03/21 Roth Capital
Roth Capital ups VBL Therapeutics target to $7 on OVAL primary endpoint update
05/18/21 Guggenheim
VBL Therapeutics initiated with a Buy at Guggenheim
VTRS Viatris
$13.57 /

-0.13 (-0.95%)

06/15/21 Citi
Viatris initiated with a Neutral at Citi
04/06/21 RBC Capital
Viatris transferred with an Outperform at RBC Capital
03/25/21 Piper Sandler
Piper says Biogen Tecfidera patents could change thesis, but sees unknowns
03/12/21 Piper Sandler
Viatris price target lowered to $16 from $17 at Piper Sandler
NVS Novartis
$83.49 /

-0.88 (-1.04%)

09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
09/07/21 Wedbush
Wedbush downgrades Xoma to Neutral, cuts target to $22
07/28/21 JPMorgan
Novartis price target raised to CHF 84 from CHF 80 at JPMorgan
07/27/21 Jefferies
Point Biopharma initiated with a Hold at Jefferies
ABBV AbbVie
$107.75 /

-0.33 (-0.31%)

AYLA Ayala Pharmaceuticals
$12.25 /

-0.01 (-0.08%)

DCPH Deciphera
$33.08 /

+1.45 (+4.58%)

LPTX Leap Therapeutics
$2.65 /

+0.13 (+5.16%)

ORIC Oric Pharmaceuticals
$25.20 /

+0.99 (+4.09%)

SYNH Syneos Health
$94.34 /

+0.55 (+0.59%)

BGNE BeiGene
$403.60 /

+18.32 (+4.75%)

BMY Bristol-Myers
$61.32 /

+0.1 (+0.16%)

BYSI BeyondSpring
$23.00 /

+0.47 (+2.09%)

CALA Calithera Biosciences
$2.25 /

+0.2 (+9.76%)

GILD Gilead
$71.61 /

+0.34 (+0.48%)

GH Guardant Health
$132.01 /

+5.01 (+3.94%)

LLY Eli Lilly
$230.17 /

-0.78 (-0.34%)

EXAS Exact Sciences
$108.29 /

+5.47 (+5.32%)

IDYA Ideaya Biosciences
$26.90 /

+0.9 (+3.46%)

GSK GlaxoSmithKline
$38.94 /

-0.16 (-0.41%)

RHHBY Roche
$46.07 /

-0.75 (-1.60%)

REGN Regeneron
$651.38 /

-2.3 (-0.35%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

TAK Takeda Pharmaceutical
$17.16 /

-0.045 (-0.26%)

TMO Thermo Fisher
$596.98 /

+36.11 (+6.44%)

TCRR TCR2 Therapeutics
$10.00 /

-5.715 (-36.38%)

VERU Veru
$8.94 /

+0.17 (+1.94%)

VBLT VBL Therapeutics
$2.32 /

-0.035 (-1.49%)

VTRS Viatris
$13.57 /

-0.13 (-0.95%)

NVS Novartis
$83.49 /

-0.88 (-1.04%)

  • 08
    Jul
  • 03
    Jun
  • 04
    May
  • 09
    Apr
  • 01
    Mar
  • 18
    Feb
  • 20
    Jan
  • 02
    Dec
  • 02
    Dec
  • 19
    Nov
  • 13
    Nov
  • 07
    Oct
ABBV AbbVie
$107.75 /

-0.33 (-0.31%)

SYNH Syneos Health
$94.34 /

+0.55 (+0.59%)

BGNE BeiGene
$403.60 /

+18.32 (+4.75%)

BMY Bristol-Myers
$61.32 /

+0.1 (+0.16%)

GILD Gilead
$71.61 /

+0.34 (+0.48%)

LLY Eli Lilly
$230.17 /

-0.78 (-0.34%)

EXAS Exact Sciences
$108.29 /

+5.47 (+5.32%)

GSK GlaxoSmithKline
$38.94 /

-0.16 (-0.41%)

RHHBY Roche
$46.07 /

-0.75 (-1.60%)

REGN Regeneron
$651.38 /

-2.3 (-0.35%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

TAK Takeda Pharmaceutical
$17.16 /

-0.045 (-0.26%)

TMO Thermo Fisher
$596.98 /

+36.11 (+6.44%)

NVS Novartis
$83.49 /

-0.88 (-1.04%)

ABBV AbbVie
$107.75 /

-0.33 (-0.31%)

GMAB Genmab
$43.10 /

+0.845 (+2.00%)

LPTX Leap Therapeutics
$2.65 /

+0.13 (+5.16%)

ORIC Oric Pharmaceuticals
$25.20 /

+0.99 (+4.09%)

BGNE BeiGene
$403.60 /

+18.32 (+4.75%)

BMY Bristol-Myers
$61.32 /

+0.1 (+0.16%)

BYSI BeyondSpring
$23.00 /

+0.47 (+2.09%)

GILD Gilead
$71.61 /

+0.34 (+0.48%)

GH Guardant Health
$132.01 /

+5.01 (+3.94%)

LLY Eli Lilly
$230.17 /

-0.78 (-0.34%)

EXAS Exact Sciences
$108.29 /

+5.47 (+5.32%)

IDYA Ideaya Biosciences
$26.90 /

+0.9 (+3.46%)

GSK GlaxoSmithKline
$38.94 /

-0.16 (-0.41%)

RHHBY Roche
$46.07 /

-0.75 (-1.60%)

REGN Regeneron
$651.38 /

-2.3 (-0.35%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

TAK Takeda Pharmaceutical
$17.16 /

-0.045 (-0.26%)

TMO Thermo Fisher
$596.98 /

+36.11 (+6.44%)

TCRR TCR2 Therapeutics
$10.00 /

-5.715 (-36.38%)

VERU Veru
$8.94 /

+0.17 (+1.94%)

NVS Novartis
$83.49 /

-0.88 (-1.04%)

ABBV AbbVie
$107.75 /

-0.33 (-0.31%)

BMY Bristol-Myers
$61.32 /

+0.1 (+0.16%)

BYSI BeyondSpring
$23.00 /

+0.47 (+2.09%)

GILD Gilead
$71.61 /

+0.34 (+0.48%)

LLY Eli Lilly
$230.17 /

-0.78 (-0.34%)

GSK GlaxoSmithKline
$38.94 /

-0.16 (-0.41%)

REGN Regeneron
$651.38 /

-2.3 (-0.35%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

TAK Takeda Pharmaceutical
$17.16 /

-0.045 (-0.26%)

TMO Thermo Fisher
$596.98 /

+36.11 (+6.44%)

VERU Veru
$8.94 /

+0.17 (+1.94%)

VTRS Viatris
$13.57 /

-0.13 (-0.95%)

Yesterday
Conference/Events
European Society for Medical Oncology to hold a virtual meeting » 04:55
09/17/21
09/17
04:55
09/17/21
04:55
ABBV

AbbVie

$108.08 /

+0.29 (+0.27%)

, AYLA

Ayala Pharmaceuticals

$12.26 /

-1.76 (-12.55%)

, DCPH

Deciphera

$31.77 /

+0.72 (+2.32%)

, GMAB

Genmab

$42.26 /

-0.575 (-1.34%)

, LPTX

Leap Therapeutics

$2.52 /

+0.57 (+29.23%)

, ORIC

Oric Pharmaceuticals

$24.49 /

-0.31 (-1.25%)

, SYNH

Syneos Health

$93.78 /

+0.07 (+0.07%)

, BGNE

BeiGene

$385.26 /

+10.94 (+2.92%)

, BMY

Bristol-Myers

$61.22 /

-0.78 (-1.26%)

, BYSI

BeyondSpring

$22.50 /

-0.48 (-2.09%)

, CALA

Calithera Biosciences

$2.05 /

-0.04 (-1.91%)

, GILD

Gilead

$71.32 /

-0.45 (-0.63%)

, GH

Guardant Health

$127.00 /

-0.01 (-0.01%)

, LLY

Eli Lilly

$230.95 /

-2.72 (-1.16%)

, IPSEY

Ipsen

$24.32 /

+0.23 (+0.95%)

, EXAS

Exact Sciences

$102.81 /

-1.83 (-1.75%)

, IDYA

Ideaya Biosciences

$25.90 /

-0.1 (-0.38%)

, GSK

GlaxoSmithKline

$39.10 /

-0.11 (-0.28%)

, RHHBY

Roche

$46.82 /

-0.04 (-0.09%)

, REGN

Regeneron

$652.73 /

+2.13 (+0.33%)

, PFE

Pfizer

$44.46 /

-0.31 (-0.69%)

, TAK

Takeda Pharmaceutical

$17.21 /

+0.205 (+1.21%)

, TMO

Thermo Fisher

$560.75 /

-2.085 (-0.37%)

, TCRR

TCR2 Therapeutics

$15.71 /

-0.51 (-3.14%)

, VERU

Veru

$8.76 /

-0.04 (-0.45%)

, VBLT

VBL Therapeutics

$2.35 /

+0.055 (+2.40%)

, VTRS

Viatris

$13.70 /

-0.03 (-0.22%)

, NVS

Novartis

$84.37 /

-0.695 (-0.82%)

ESMO 2021 Virtual…

ESMO 2021 Virtual Congress will be held on September 16-21. Webcast Link

ShowHide Related Items >><<
VTRS Viatris
$13.70 /

-0.03 (-0.22%)

VERU Veru
$8.76 /

-0.04 (-0.45%)

VBLT VBL Therapeutics
$2.35 /

+0.055 (+2.40%)

TMO Thermo Fisher
$560.75 /

-2.085 (-0.37%)

TCRR TCR2 Therapeutics
$15.71 /

-0.51 (-3.14%)

TAK Takeda Pharmaceutical
$17.21 /

+0.205 (+1.21%)

SYNH Syneos Health
$93.78 /

+0.07 (+0.07%)

RHHBY Roche
$46.82 /

-0.04 (-0.09%)

REGN Regeneron
$652.73 /

+2.13 (+0.33%)

PFE Pfizer
$44.46 /

-0.31 (-0.69%)

ORIC Oric Pharmaceuticals
$24.49 /

-0.31 (-1.25%)

NVS Novartis
$84.37 /

-0.695 (-0.82%)

LPTX Leap Therapeutics
$2.52 /

+0.57 (+29.23%)

LLY Eli Lilly
$230.95 /

-2.72 (-1.16%)

IPSEY Ipsen
$24.32 /

+0.23 (+0.95%)

IDYA Ideaya Biosciences
$25.90 /

-0.1 (-0.38%)

GSK GlaxoSmithKline
$39.10 /

-0.11 (-0.28%)

GMAB Genmab
$42.26 /

-0.575 (-1.34%)

GILD Gilead
$71.32 /

-0.45 (-0.63%)

GH Guardant Health
$127.00 /

-0.01 (-0.01%)

EXAS Exact Sciences
$102.81 /

-1.83 (-1.75%)

DCPH Deciphera
$31.77 /

+0.72 (+2.32%)

CALA Calithera Biosciences
$2.05 /

-0.04 (-1.91%)

BYSI BeyondSpring
$22.50 /

-0.48 (-2.09%)

BMY Bristol-Myers
$61.22 /

-0.78 (-1.26%)

BGNE BeiGene
$385.26 /

+10.94 (+2.92%)

AYLA Ayala Pharmaceuticals
$12.26 /

-1.76 (-12.55%)

ABBV AbbVie
$108.08 /

+0.29 (+0.27%)

ABBV AbbVie
$108.08 /

+0.29 (+0.27%)

09/14/21 Barclays
Regenxbio price target raised to $82 from $79 at Barclays
09/13/21 Chardan
Regenxbio pact with AbbVie accelerates RGX-314 'value capture,' says Chardan
09/08/21 JPMorgan
AbbVie offers 'best risk/reward story in the group,' says JPMorgan
09/07/21 Morgan Stanley
Morgan Stanley cuts Vertex Pharmaceuticals to Underweight amid AbbVie overhang
AYLA Ayala Pharmaceuticals
$12.26 /

-1.76 (-12.55%)

07/13/21 Ladenburg
Ayala Pharmaceuticals initiated with Buy, $29 target at Ladenburg
07/13/21 Ladenburg
Ayala Pharmaceuticals initiated with a Buy at Ladenburg
12/07/20
Fly Intel: Top five analyst initiations
12/07/20 Roth Capital
Ayala Pharmaceuticals initiated with a Buy at Roth Capital
DCPH Deciphera
$31.77 /

+0.72 (+2.32%)

08/04/21 H.C. Wainwright
Deciphera price target lowered to $70 from $75 at H.C. Wainwright
05/05/21 Barclays
Deciphera price target lowered to $65 from $70 at Barclays
05/05/21 H.C. Wainwright
Deciphera price target lowered to $75 from $80 at H.C. Wainwright
05/05/21 Piper Sandler
Deciphera price target lowered to $60 from $75 at Piper Sandler
GMAB Genmab
$42.26 /

-0.575 (-1.34%)

09/16/21
Fly Intel: Top five analyst downgrades
09/16/21 Jefferies
Genmab downgraded to Hold from Buy at Jefferies
09/07/21
Fly Intel: Top five analyst downgrades
09/07/21 Morgan Stanley
Morgan Stanley cuts Genmab to Underweight amid high investor expectations
LPTX Leap Therapeutics
$2.52 /

+0.57 (+29.23%)

09/16/21 Piper Sandler
Leap data show 'very favorable early signal,' says Piper Sandler
09/13/21 Raymond James
Leap Therapeutics price target raised to $4 from $3 at Raymond James
09/13/21 Piper Sandler
Leap combo sees 'strong' early response rate, says Piper Sandler
06/03/21 Baird
Leap Therapeutics transferred with Outperform at Baird
ORIC Oric Pharmaceuticals
$24.49 /

-0.31 (-1.25%)

07/06/21 Citi
Oric Pharmaceuticals upgraded to Buy after tumor data at Citi
07/06/21 Citi
Oric Pharmaceuticals upgraded to Buy from Neutral at Citi
03/25/21 H.C. Wainwright
Oric Pharmaceuticals price target raised to $54 from $52 at H.C. Wainwright
01/25/21 Citi
Oric Pharmaceuticals downgraded to Neutral from Buy at Citi
SYNH Syneos Health
$93.78 /

+0.07 (+0.07%)

08/04/21 Credit Suisse
Syneos Health assumed with an Outperform at Credit Suisse
07/13/21 Barclays
Syneos Health price target raised to $102 from $90 at Barclays
06/02/21 Truist
Syneos Health price target raised to $104 from $88 at Truist
04/30/21 Mizuho
Syneos Health price target raised to $90 from $82 at Mizuho
BGNE BeiGene
$385.26 /

+10.94 (+2.92%)

06/14/21 SVB Leerink
BeiGene price target raised to $417 from $388 at SVB Leerink
03/16/21 HSBC
BeiGene price target raised to $385 from $296 at HSBC
03/08/21 China Renaissance
BeiGene initiated with a Buy at China Renaissance
03/04/21 Goldman Sachs
Five Prime acquisition 'a strategic positive' for Amgen, says Goldman Sachs
BMY Bristol-Myers
$61.22 /

-0.78 (-1.26%)

09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
07/27/21 Mizuho
Bristol-Myers deal a positive signal about BridgeBio's BBP-398, says Mizuho
07/26/21 Truist
Bristol-Myers assumed with a Buy at Truist
07/26/21 Truist
Bristol-Myers assumed with a Buy at Truist
BYSI BeyondSpring
$22.50 /

-0.48 (-2.09%)

09/08/21 Baird
BeyondSpring initiated with an Outperform at Baird
08/04/21 Evercore ISI
BeyondSpring price target raised to $95 from $30 at Evercore ISI
08/04/21 William Blair
BeyondSpring may have new standard of care in lung cancer, says William Blair
08/04/21 H.C. Wainwright
Wainwright upgrades BeyondSpring with $100 target on lung cancer data
CALA Calithera Biosciences
$2.05 /

-0.04 (-1.91%)

01/05/21 SVB Leerink
Calithera Biosciences downgraded to Market Perform at SVB Leerink
01/05/21 SVB Leerink
Calithera Biosciences downgraded to Market Perform from Outperform at SVB Leerink
01/05/21 Citi
Calithera Biosciences price target lowered to $5 from $10 at Citi
01/05/21 H.C. Wainwright
Calithera Biosciences price target lowered to $4 from $9.50 at H.C. Wainwright
GILD Gilead
$71.32 /

-0.45 (-0.63%)

07/30/21 BMO Capital
Gilead price target raised to $72 from $67 at BMO Capital
07/30/21 RBC Capital
Gilead price target raised to $84 from $81 at RBC Capital
06/29/21 Jefferies
Gilead data should move Yescarta up to second line in DLBCL, says Jefferies
GH Guardant Health
$127.00 /

-0.01 (-0.01%)

08/09/21 Canaccord
Guardant Health price target lowered to $180 from $195 at Canaccord
06/21/21 Wells Fargo
Guardant Health price target raised to $160 from $145 at Wells Fargo
06/15/21
Fly Intel: Top five analyst initiations
06/15/21 Raymond James
Guardant Health initiated with a Market Perform at Raymond James
LLY Eli Lilly
$230.95 /

-2.72 (-1.16%)

09/02/21 SVB Leerink
AbbVie price target lowered to $142 from $148 at SVB Leerink
08/30/21 Cowen
Eli Lilly price target raised to $300 from $250 at Cowen
08/30/21 Citi
Lexicon price target raised to $20 from $13 at Citi
IPSEY Ipsen
$24.32 /

+0.23 (+0.95%)

08/16/21 Morgan Stanley
Ipsen price target lowered to EUR 88 from EUR 92 at Morgan Stanley
08/03/21 Morgan Stanley
Ipsen price target raised to EUR 92 from EUR 85 at Morgan Stanley
08/02/21 Societe Generale
Ipsen price target raised to EUR 101 from EUR 90 at Societe Generale
07/30/21 Credit Suisse
Ipsen price target raised to EUR 90 from EUR 75 at Credit Suisse
EXAS Exact Sciences
$102.81 /

-1.83 (-1.75%)

09/16/21 Canaccord
Exact Sciences salesforce expansion a net positive, says Canaccord
09/15/21 Raymond James
Exact Sciences' 'opportunistic' hires should boost sales, says Raymond James
09/15/21 Canaccord
Exact Sciences progress in MRD space a positive, says Canaccord
09/01/21 Baird
UnitedHealth update to CRC screening coverage not a surprise, says Baird
IDYA Ideaya Biosciences
$25.90 /

-0.1 (-0.38%)

06/03/21 Baird
Ideaya Biosciences assumed with an Outperform at Baird
04/22/21 Roth Capital
Ideaya Biosciences price target raised to $38 from $31 at Roth Capital
04/19/21 H.C. Wainwright
Ideaya Biosciences price target raised to $35 from $29 at H.C. Wainwright
04/16/21 Roth Capital
Ideaya Biosciences price target raised to $31 from $23 at Roth Capital
GSK GlaxoSmithKline
$39.10 /

-0.11 (-0.28%)

08/26/21 UBS
GlaxoSmithKline price target raised to 1,540 GBp from 1,485 GBp at UBS
08/20/21 JPMorgan
GlaxoSmithKline price target raised to 1,500 GBp from 1,300 GBp at JPMorgan
08/19/21 Berenberg
GlaxoSmithKline price target raised to 1,625 GBp from 1,570 GBp at Berenberg
RHHBY Roche
$46.82 /

-0.04 (-0.09%)

09/07/21 UBS
Roche price target raised to CHF 350 from CHF 345 at UBS
08/02/21 JPMorgan
Roche price target raised to CHF 360 from CHF 310 at JPMorgan
07/27/21 Societe Generale
Roche price target raised to CHF 353 from CHF 340 at Societe Generale
REGN Regeneron
$652.73 /

+2.13 (+0.33%)

09/15/21 Cantor Fitzgerald
Regeneron price target raised to $700 from $670 at Cantor Fitzgerald
09/15/21 H.C. Wainwright
Regeneron price target raised to $831 from $787 at H.C. Wainwright
09/15/21 Piper Sandler
Regeneron price target raised to $690 from $675 at Piper Sandler
09/09/21
Fly Intel: Top five analyst initiations
PFE Pfizer
$44.46 /

-0.31 (-0.69%)

09/16/21 BofA
Moderna boosters already reflected in 'bullish' consensus, says BofA
09/13/21 JPMorgan
Pfizer price target raised to $42 from $40 at JPMorgan
TAK Takeda Pharmaceutical
$17.21 /

+0.205 (+1.21%)

08/03/21 Piper Sandler
Arcturus strength attributable to large pharma's interest in mRNA, says Piper
04/27/21 Chardan
LogicBio collaborations may signal recognition of platforms, says Chardan
04/19/21 JPMorgan
Takeda Pharmaceutical downgraded to Neutral on R&D investments at JPMorgan
04/19/21 JPMorgan
Takeda Pharmaceutical downgraded to Neutral from Overweight at JPMorgan
TMO Thermo Fisher
$560.75 /

-2.085 (-0.37%)

08/04/21 Credit Suisse
Thermo Fisher assumed with an Outperform at Credit Suisse
08/04/21 Argus
Thermo Fisher price target raised to $600 from $530 at Argus
07/29/21 Cowen
Thermo Fisher price target raised to $560 from $525 at Cowen
07/29/21 BTIG
Thermo Fisher price target raised to $610 from $590 at BTIG
TCRR TCR2 Therapeutics
$15.71 /

-0.51 (-3.14%)

08/06/21 BMO Capital
TCR2 Therapeutics price target lowered to $44 from $53 at BMO Capital
06/24/21 Goldman Sachs
TCR2 Therapeutics initiated with a Buy at Goldman Sachs
06/11/21 BMO Capital
TCR2 Therapeutics coverage transferred at BMO Capital
05/14/21 Wedbush
TCR2 Therapeutics price target lowered to $45 from $57 at Wedbush
VERU Veru
$8.76 /

-0.04 (-0.45%)

04/13/21 Jefferies
Veru initiated with a Buy at Jefferies
02/11/21 Oppenheimer
Veru price target raised to $24 from $19 at Oppenheimer
02/11/21 H.C. Wainwright
Veru price target raised to $22 from $17 at H.C. Wainwright
02/09/21 H.C. Wainwright
Veru price target raised to $17 from $12 at H.C. Wainwright
VBLT VBL Therapeutics
$2.35 /

+0.055 (+2.40%)

08/30/21 Roth Capital
Roth bullish on VBL Therapeutics as U.S. Phase 3 OVAL trial enrollment resumes
06/15/21 Roth Capital
Roth does not see material change to VBL readout timelines
06/03/21 Roth Capital
Roth Capital ups VBL Therapeutics target to $7 on OVAL primary endpoint update
05/18/21 Guggenheim
VBL Therapeutics initiated with a Buy at Guggenheim
VTRS Viatris
$13.70 /

-0.03 (-0.22%)

06/15/21 Citi
Viatris initiated with a Neutral at Citi
04/06/21 RBC Capital
Viatris transferred with an Outperform at RBC Capital
03/25/21 Piper Sandler
Piper says Biogen Tecfidera patents could change thesis, but sees unknowns
03/12/21 Piper Sandler
Viatris price target lowered to $16 from $17 at Piper Sandler
NVS Novartis
$84.37 /

-0.695 (-0.82%)

09/07/21 Wedbush
Wedbush downgrades Xoma to Neutral, cuts target to $22
07/28/21 JPMorgan
Novartis price target raised to CHF 84 from CHF 80 at JPMorgan
07/27/21 Jefferies
Point Biopharma initiated with a Hold at Jefferies
VTRS Viatris
$13.70 /

-0.03 (-0.22%)

VERU Veru
$8.76 /

-0.04 (-0.45%)

VBLT VBL Therapeutics
$2.35 /

+0.055 (+2.40%)

TMO Thermo Fisher
$560.75 /

-2.085 (-0.37%)

TCRR TCR2 Therapeutics
$15.71 /

-0.51 (-3.14%)

TAK Takeda Pharmaceutical
$17.21 /

+0.205 (+1.21%)

SYNH Syneos Health
$93.78 /

+0.07 (+0.07%)

RHHBY Roche
$46.82 /

-0.04 (-0.09%)

REGN Regeneron
$652.73 /

+2.13 (+0.33%)

PFE Pfizer
$44.46 /

-0.31 (-0.69%)

ORIC Oric Pharmaceuticals
$24.49 /

-0.31 (-1.25%)

NVS Novartis
$84.37 /

-0.695 (-0.82%)

LPTX Leap Therapeutics
$2.52 /

+0.57 (+29.23%)

LLY Eli Lilly
$230.95 /

-2.72 (-1.16%)

IDYA Ideaya Biosciences
$25.90 /

-0.1 (-0.38%)

GSK GlaxoSmithKline
$39.10 /

-0.11 (-0.28%)

GILD Gilead
$71.32 /

-0.45 (-0.63%)

GH Guardant Health
$127.00 /

-0.01 (-0.01%)

EXAS Exact Sciences
$102.81 /

-1.83 (-1.75%)

DCPH Deciphera
$31.77 /

+0.72 (+2.32%)

CALA Calithera Biosciences
$2.05 /

-0.04 (-1.91%)

BYSI BeyondSpring
$22.50 /

-0.48 (-2.09%)

BMY Bristol-Myers
$61.22 /

-0.78 (-1.26%)

BGNE BeiGene
$385.26 /

+10.94 (+2.92%)

AYLA Ayala Pharmaceuticals
$12.26 /

-1.76 (-12.55%)

ABBV AbbVie
$108.08 /

+0.29 (+0.27%)

  • 08
    Jul
  • 03
    Jun
  • 04
    May
  • 09
    Apr
  • 01
    Mar
  • 18
    Feb
  • 20
    Jan
  • 02
    Dec
  • 02
    Dec
  • 19
    Nov
  • 13
    Nov
  • 07
    Oct
TMO Thermo Fisher
$560.75 /

-2.085 (-0.37%)

TAK Takeda Pharmaceutical
$17.21 /

+0.205 (+1.21%)

SYNH Syneos Health
$93.78 /

+0.07 (+0.07%)

RHHBY Roche
$46.82 /

-0.04 (-0.09%)

REGN Regeneron
$652.73 /

+2.13 (+0.33%)

PFE Pfizer
$44.46 /

-0.31 (-0.69%)

NVS Novartis
$84.37 /

-0.695 (-0.82%)

LLY Eli Lilly
$230.95 /

-2.72 (-1.16%)

GSK GlaxoSmithKline
$39.10 /

-0.11 (-0.28%)

GILD Gilead
$71.32 /

-0.45 (-0.63%)

EXAS Exact Sciences
$102.81 /

-1.83 (-1.75%)

BMY Bristol-Myers
$61.22 /

-0.78 (-1.26%)

BGNE BeiGene
$385.26 /

+10.94 (+2.92%)

ABBV AbbVie
$108.08 /

+0.29 (+0.27%)

VERU Veru
$8.76 /

-0.04 (-0.45%)

TMO Thermo Fisher
$560.75 /

-2.085 (-0.37%)

TAK Takeda Pharmaceutical
$17.21 /

+0.205 (+1.21%)

RHHBY Roche
$46.82 /

-0.04 (-0.09%)

REGN Regeneron
$652.73 /

+2.13 (+0.33%)

PFE Pfizer
$44.46 /

-0.31 (-0.69%)

ORIC Oric Pharmaceuticals
$24.49 /

-0.31 (-1.25%)

NVS Novartis
$84.37 /

-0.695 (-0.82%)

LPTX Leap Therapeutics
$2.52 /

+0.57 (+29.23%)

LLY Eli Lilly
$230.95 /

-2.72 (-1.16%)

IDYA Ideaya Biosciences
$25.90 /

-0.1 (-0.38%)

GSK GlaxoSmithKline
$39.10 /

-0.11 (-0.28%)

GMAB Genmab
$42.26 /

-0.575 (-1.34%)

GILD Gilead
$71.32 /

-0.45 (-0.63%)

GH Guardant Health
$127.00 /

-0.01 (-0.01%)

EXAS Exact Sciences
$102.81 /

-1.83 (-1.75%)

BYSI BeyondSpring
$22.50 /

-0.48 (-2.09%)

BMY Bristol-Myers
$61.22 /

-0.78 (-1.26%)

ABBV AbbVie
$108.08 /

+0.29 (+0.27%)

VTRS Viatris
$13.70 /

-0.03 (-0.22%)

VERU Veru
$8.76 /

-0.04 (-0.45%)

TAK Takeda Pharmaceutical
$17.21 /

+0.205 (+1.21%)

REGN Regeneron
$652.73 /

+2.13 (+0.33%)

PFE Pfizer
$44.46 /

-0.31 (-0.69%)

LLY Eli Lilly
$230.95 /

-2.72 (-1.16%)

GSK GlaxoSmithKline
$39.10 /

-0.11 (-0.28%)

GILD Gilead
$71.32 /

-0.45 (-0.63%)

BYSI BeyondSpring
$22.50 /

-0.48 (-2.09%)

BMY Bristol-Myers
$61.22 /

-0.78 (-1.26%)

ABBV AbbVie
$108.08 /

+0.29 (+0.27%)

Thursday
Hot Stocks
Eli Lilly says FDA expands EUA for bamlanivimab-etesevimab combo » 15:58
09/16/21
09/16
15:58
09/16/21
15:58
LLY

Eli Lilly

$231.47 /

-2.2 (-0.94%)

The U.S. Food and Drug…

The U.S. Food and Drug Administration has expanded the Emergency Use Authorization for bamlanivimab 700 mg and etesevimab 1400 mg administered together to include post-exposure prophylaxis in certain individuals for the prevention of SARS-CoV-2 infection, Eli Lilly and Company announced. The neutralizing antibodies can now be used together to treat high-risk individuals 12 years of age and older who have not been fully vaccinated against COVID-19 or are not expected to mount an adequate immune response to complete vaccination, and have been exposed to someone infected with SARS-CoV-2 or who are at high risk of exposure in an institutional setting, including a nursing home or prison. This authorization follows the national reopening of distribution earlier this month. The expanded authorization is based on data from BLAZE-2, a study conducted in partnership with the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, and the COVID-19 Prevention Network, that enrolled residents and staff at long-term care facilities, commonly referred to as nursing homes, across the U.S. In this placebo-controlled Phase 3 study, bamlanivimab 4200 mg reduced the risk of contracting symptomatic COVID-19 by up to 80 percent in nursing home residents and up to 57 percent among residents and staff of long-term care facilities.

ShowHide Related Items >><<
LLY Eli Lilly
$231.47 /

-2.2 (-0.94%)

LLY Eli Lilly
$231.47 /

-2.2 (-0.94%)

09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
09/02/21 SVB Leerink
AbbVie price target lowered to $142 from $148 at SVB Leerink
08/30/21 Cowen
Eli Lilly price target raised to $300 from $250 at Cowen
08/30/21 Citi
Lexicon price target raised to $20 from $13 at Citi
LLY Eli Lilly
$231.47 /

-2.2 (-0.94%)

LLY Eli Lilly
$231.47 /

-2.2 (-0.94%)

LLY Eli Lilly
$231.47 /

-2.2 (-0.94%)

LLY Eli Lilly
$231.47 /

-2.2 (-0.94%)

Hot Stocks
FDA authorizes Lilly's antibody combo for COVID post-exposure prophylaxis » 15:21
09/16/21
09/16
15:21
09/16/21
15:21
LLY

Eli Lilly

$231.56 /

-2.11 (-0.90%)

The FDA stated in a…

The FDA stated in a letter posted to its website that on September 16, 2021, "again having concluded that revising this EUA is appropriate to protect the public health or safety," FDA is reissuing the August 27, 2021 letter in its entirety, to also authorize bamlanivimab and etesevimab administered together for emergency use as post-exposure prophylaxis in certain adults and pediatric individuals. Previously, the FDA had issued an Emergency Use Authorization, or EUA, for emergency use of bamlanivimab and etesevimab administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization. Reference Link

ShowHide Related Items >><<
LLY Eli Lilly
$231.56 /

-2.11 (-0.90%)

LLY Eli Lilly
$231.56 /

-2.11 (-0.90%)

09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
09/02/21 SVB Leerink
AbbVie price target lowered to $142 from $148 at SVB Leerink
08/30/21 Cowen
Eli Lilly price target raised to $300 from $250 at Cowen
08/30/21 Citi
Lexicon price target raised to $20 from $13 at Citi
LLY Eli Lilly
$231.56 /

-2.11 (-0.90%)

LLY Eli Lilly
$231.56 /

-2.11 (-0.90%)

LLY Eli Lilly
$231.56 /

-2.11 (-0.90%)

LLY Eli Lilly
$231.56 /

-2.11 (-0.90%)

Conference/Events
European Society for Medical Oncology to hold a virtual meeting » 10:09
09/16/21
09/16
10:09
09/16/21
10:09
ABBV

AbbVie

$107.05 /

-0.74 (-0.69%)

, AYLA

Ayala Pharmaceuticals

$14.30 /

+0.28 (+2.00%)

, DCPH

Deciphera

$30.40 /

-0.65 (-2.09%)

, GMAB

Genmab

$42.26 /

-0.57 (-1.33%)

, LPTX

Leap Therapeutics

$2.34 /

+0.39 (+20.00%)

, ORIC

Oric Pharmaceuticals

$25.02 /

+0.22 (+0.89%)

, SYNH

Syneos Health

$93.28 /

-0.43 (-0.46%)

, BGNE

BeiGene

$377.63 /

+3.31 (+0.88%)

, BMY

Bristol-Myers

$61.18 /

-0.82 (-1.32%)

, BYSI

BeyondSpring

$22.25 /

-0.73 (-3.18%)

, CALA

Calithera Biosciences

$2.06 /

-0.03 (-1.44%)

, GILD

Gilead

$71.34 /

-0.43 (-0.60%)

, GH

Guardant Health

$126.36 /

-0.65 (-0.51%)

, LLY

Eli Lilly

$231.73 /

-1.94 (-0.83%)

, IPSEY

Ipsen

$24.09 /

-0.115 (-0.48%)

, EXAS

Exact Sciences

$102.18 /

-2.46 (-2.35%)

, IDYA

Ideaya Biosciences

$25.87 /

-0.13 (-0.50%)

, GSK

GlaxoSmithKline

$38.92 /

-0.29 (-0.74%)

, RHHBY

Roche

$46.86 /

+0.11 (+0.24%)

, REGN

Regeneron

$647.54 /

-3.06 (-0.47%)

, PFE

Pfizer

$44.70 /

-0.07 (-0.16%)

, TAK

Takeda Pharmaceutical

$17.14 /

+0.14 (+0.82%)

, TMO

Thermo Fisher

$558.70 /

-4.135 (-0.73%)

, TCRR

TCR2 Therapeutics

$16.17 /

-0.05 (-0.31%)

, VERU

Veru

$8.70 /

-0.1 (-1.14%)

, VBLT

VBL Therapeutics

$2.30 /

+0.005 (+0.22%)

, VTRS

Viatris

$13.78 /

+0.05 (+0.36%)

, NVS

Novartis

$84.33 /

-0.735 (-0.86%)

ESMO 2021 Virtual…

ESMO 2021 Virtual Congress will be held on September 16-21. Webcast Link

ShowHide Related Items >><<
VTRS Viatris
$13.78 /

+0.05 (+0.36%)

VERU Veru
$8.70 /

-0.1 (-1.14%)

VBLT VBL Therapeutics
$2.30 /

+0.005 (+0.22%)

TMO Thermo Fisher
$558.70 /

-4.135 (-0.73%)

TCRR TCR2 Therapeutics
$16.17 /

-0.05 (-0.31%)

TAK Takeda Pharmaceutical
$17.14 /

+0.14 (+0.82%)

SYNH Syneos Health
$93.28 /

-0.43 (-0.46%)

RHHBY Roche
$46.86 /

+0.11 (+0.24%)

REGN Regeneron
$647.54 /

-3.06 (-0.47%)

PFE Pfizer
$44.70 /

-0.07 (-0.16%)

ORIC Oric Pharmaceuticals
$25.02 /

+0.22 (+0.89%)

NVS Novartis
$84.33 /

-0.735 (-0.86%)

LPTX Leap Therapeutics
$2.34 /

+0.39 (+20.00%)

LLY Eli Lilly
$231.73 /

-1.94 (-0.83%)

IPSEY Ipsen
$24.09 /

-0.115 (-0.48%)

IDYA Ideaya Biosciences
$25.87 /

-0.13 (-0.50%)

GSK GlaxoSmithKline
$38.92 /

-0.29 (-0.74%)

GMAB Genmab
$42.26 /

-0.57 (-1.33%)

GILD Gilead
$71.34 /

-0.43 (-0.60%)

GH Guardant Health
$126.36 /

-0.65 (-0.51%)

EXAS Exact Sciences
$102.18 /

-2.46 (-2.35%)

DCPH Deciphera
$30.40 /

-0.65 (-2.09%)

CALA Calithera Biosciences
$2.06 /

-0.03 (-1.44%)

BYSI BeyondSpring
$22.25 /

-0.73 (-3.18%)

BMY Bristol-Myers
$61.18 /

-0.82 (-1.32%)

BGNE BeiGene
$377.63 /

+3.31 (+0.88%)

AYLA Ayala Pharmaceuticals
$14.30 /

+0.28 (+2.00%)

ABBV AbbVie
$107.05 /

-0.74 (-0.69%)

ABBV AbbVie
$107.05 /

-0.74 (-0.69%)

09/14/21 Barclays
Regenxbio price target raised to $82 from $79 at Barclays
09/13/21 Chardan
Regenxbio pact with AbbVie accelerates RGX-314 'value capture,' says Chardan
09/08/21 JPMorgan
AbbVie offers 'best risk/reward story in the group,' says JPMorgan
09/07/21 Morgan Stanley
Morgan Stanley cuts Vertex Pharmaceuticals to Underweight amid AbbVie overhang
AYLA Ayala Pharmaceuticals
$14.30 /

+0.28 (+2.00%)

07/13/21 Ladenburg
Ayala Pharmaceuticals initiated with Buy, $29 target at Ladenburg
07/13/21 Ladenburg
Ayala Pharmaceuticals initiated with a Buy at Ladenburg
12/07/20
Fly Intel: Top five analyst initiations
12/07/20 Roth Capital
Ayala Pharmaceuticals initiated with a Buy at Roth Capital
DCPH Deciphera
$30.40 /

-0.65 (-2.09%)

08/04/21 H.C. Wainwright
Deciphera price target lowered to $70 from $75 at H.C. Wainwright
05/05/21 Barclays
Deciphera price target lowered to $65 from $70 at Barclays
05/05/21 H.C. Wainwright
Deciphera price target lowered to $75 from $80 at H.C. Wainwright
05/05/21 Piper Sandler
Deciphera price target lowered to $60 from $75 at Piper Sandler
GMAB Genmab
$42.26 /

-0.57 (-1.33%)

09/16/21
Fly Intel: Top five analyst downgrades
09/16/21 Jefferies
Genmab downgraded to Hold from Buy at Jefferies
09/07/21
Fly Intel: Top five analyst downgrades
09/07/21 Morgan Stanley
Morgan Stanley cuts Genmab to Underweight amid high investor expectations
LPTX Leap Therapeutics
$2.34 /

+0.39 (+20.00%)

09/16/21 Piper Sandler
Leap data show 'very favorable early signal,' says Piper Sandler
09/13/21 Raymond James
Leap Therapeutics price target raised to $4 from $3 at Raymond James
09/13/21 Piper Sandler
Leap combo sees 'strong' early response rate, says Piper Sandler
06/03/21 Baird
Leap Therapeutics transferred with Outperform at Baird
ORIC Oric Pharmaceuticals
$25.02 /

+0.22 (+0.89%)

07/06/21 Citi
Oric Pharmaceuticals upgraded to Buy after tumor data at Citi
07/06/21 Citi
Oric Pharmaceuticals upgraded to Buy from Neutral at Citi
03/25/21 H.C. Wainwright
Oric Pharmaceuticals price target raised to $54 from $52 at H.C. Wainwright
01/25/21 Citi
Oric Pharmaceuticals downgraded to Neutral from Buy at Citi
SYNH Syneos Health
$93.28 /

-0.43 (-0.46%)

08/04/21 Credit Suisse
Syneos Health assumed with an Outperform at Credit Suisse
07/13/21 Barclays
Syneos Health price target raised to $102 from $90 at Barclays
06/02/21 Truist
Syneos Health price target raised to $104 from $88 at Truist
04/30/21 Mizuho
Syneos Health price target raised to $90 from $82 at Mizuho
BGNE BeiGene
$377.63 /

+3.31 (+0.88%)

06/14/21 SVB Leerink
BeiGene price target raised to $417 from $388 at SVB Leerink
03/16/21 HSBC
BeiGene price target raised to $385 from $296 at HSBC
03/08/21 China Renaissance
BeiGene initiated with a Buy at China Renaissance
03/04/21 Goldman Sachs
Five Prime acquisition 'a strategic positive' for Amgen, says Goldman Sachs
BMY Bristol-Myers
$61.18 /

-0.82 (-1.32%)

09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
07/27/21 Mizuho
Bristol-Myers deal a positive signal about BridgeBio's BBP-398, says Mizuho
07/26/21 Truist
Bristol-Myers assumed with a Buy at Truist
07/26/21 Truist
Bristol-Myers assumed with a Buy at Truist
BYSI BeyondSpring
$22.25 /

-0.73 (-3.18%)

09/08/21 Baird
BeyondSpring initiated with an Outperform at Baird
08/04/21 Evercore ISI
BeyondSpring price target raised to $95 from $30 at Evercore ISI
08/04/21 William Blair
BeyondSpring may have new standard of care in lung cancer, says William Blair
08/04/21 H.C. Wainwright
Wainwright upgrades BeyondSpring with $100 target on lung cancer data
CALA Calithera Biosciences
$2.06 /

-0.03 (-1.44%)

01/05/21 SVB Leerink
Calithera Biosciences downgraded to Market Perform at SVB Leerink
01/05/21 SVB Leerink
Calithera Biosciences downgraded to Market Perform from Outperform at SVB Leerink
01/05/21 Citi
Calithera Biosciences price target lowered to $5 from $10 at Citi
01/05/21 H.C. Wainwright
Calithera Biosciences price target lowered to $4 from $9.50 at H.C. Wainwright
GILD Gilead
$71.34 /

-0.43 (-0.60%)

07/30/21 BMO Capital
Gilead price target raised to $72 from $67 at BMO Capital
07/30/21 RBC Capital
Gilead price target raised to $84 from $81 at RBC Capital
06/29/21 Jefferies
Gilead data should move Yescarta up to second line in DLBCL, says Jefferies
GH Guardant Health
$126.36 /

-0.65 (-0.51%)

08/09/21 Canaccord
Guardant Health price target lowered to $180 from $195 at Canaccord
06/21/21 Wells Fargo
Guardant Health price target raised to $160 from $145 at Wells Fargo
06/15/21
Fly Intel: Top five analyst initiations
06/15/21 Raymond James
Guardant Health initiated with a Market Perform at Raymond James
LLY Eli Lilly
$231.73 /

-1.94 (-0.83%)

09/02/21 SVB Leerink
AbbVie price target lowered to $142 from $148 at SVB Leerink
08/30/21 Cowen
Eli Lilly price target raised to $300 from $250 at Cowen
08/30/21 Citi
Lexicon price target raised to $20 from $13 at Citi
IPSEY Ipsen
$24.09 /

-0.115 (-0.48%)

08/16/21 Morgan Stanley
Ipsen price target lowered to EUR 88 from EUR 92 at Morgan Stanley
08/03/21 Morgan Stanley
Ipsen price target raised to EUR 92 from EUR 85 at Morgan Stanley
08/02/21 Societe Generale
Ipsen price target raised to EUR 101 from EUR 90 at Societe Generale
07/30/21 Credit Suisse
Ipsen price target raised to EUR 90 from EUR 75 at Credit Suisse
EXAS Exact Sciences
$102.18 /

-2.46 (-2.35%)

09/16/21 Canaccord
Exact Sciences salesforce expansion a net positive, says Canaccord
09/15/21 Raymond James
Exact Sciences' 'opportunistic' hires should boost sales, says Raymond James
09/15/21 Canaccord
Exact Sciences progress in MRD space a positive, says Canaccord
09/01/21 Baird
UnitedHealth update to CRC screening coverage not a surprise, says Baird
IDYA Ideaya Biosciences
$25.87 /

-0.13 (-0.50%)

06/03/21 Baird
Ideaya Biosciences assumed with an Outperform at Baird
04/22/21 Roth Capital
Ideaya Biosciences price target raised to $38 from $31 at Roth Capital
04/19/21 H.C. Wainwright
Ideaya Biosciences price target raised to $35 from $29 at H.C. Wainwright
04/16/21 Roth Capital
Ideaya Biosciences price target raised to $31 from $23 at Roth Capital
GSK GlaxoSmithKline
$38.92 /

-0.29 (-0.74%)

08/26/21 UBS
GlaxoSmithKline price target raised to 1,540 GBp from 1,485 GBp at UBS
08/20/21 JPMorgan
GlaxoSmithKline price target raised to 1,500 GBp from 1,300 GBp at JPMorgan
08/19/21 Berenberg
GlaxoSmithKline price target raised to 1,625 GBp from 1,570 GBp at Berenberg
RHHBY Roche
$46.86 /

+0.11 (+0.24%)

09/07/21 UBS
Roche price target raised to CHF 350 from CHF 345 at UBS
08/02/21 JPMorgan
Roche price target raised to CHF 360 from CHF 310 at JPMorgan
07/27/21 Societe Generale
Roche price target raised to CHF 353 from CHF 340 at Societe Generale
REGN Regeneron
$647.54 /

-3.06 (-0.47%)

09/15/21 Cantor Fitzgerald
Regeneron price target raised to $700 from $670 at Cantor Fitzgerald
09/15/21 H.C. Wainwright
Regeneron price target raised to $831 from $787 at H.C. Wainwright
09/15/21 Piper Sandler
Regeneron price target raised to $690 from $675 at Piper Sandler
09/09/21
Fly Intel: Top five analyst initiations
PFE Pfizer
$44.70 /

-0.07 (-0.16%)

09/16/21 BofA
Moderna boosters already reflected in 'bullish' consensus, says BofA
09/13/21 JPMorgan
Pfizer price target raised to $42 from $40 at JPMorgan
TAK Takeda Pharmaceutical
$17.14 /

+0.14 (+0.82%)

08/03/21 Piper Sandler
Arcturus strength attributable to large pharma's interest in mRNA, says Piper
04/27/21 Chardan
LogicBio collaborations may signal recognition of platforms, says Chardan
04/19/21 JPMorgan
Takeda Pharmaceutical downgraded to Neutral on R&D investments at JPMorgan
04/19/21 JPMorgan
Takeda Pharmaceutical downgraded to Neutral from Overweight at JPMorgan
TMO Thermo Fisher
$558.70 /

-4.135 (-0.73%)

08/04/21 Credit Suisse
Thermo Fisher assumed with an Outperform at Credit Suisse
08/04/21 Argus
Thermo Fisher price target raised to $600 from $530 at Argus
07/29/21 Cowen
Thermo Fisher price target raised to $560 from $525 at Cowen
07/29/21 BTIG
Thermo Fisher price target raised to $610 from $590 at BTIG
TCRR TCR2 Therapeutics
$16.17 /

-0.05 (-0.31%)

08/06/21 BMO Capital
TCR2 Therapeutics price target lowered to $44 from $53 at BMO Capital
06/24/21 Goldman Sachs
TCR2 Therapeutics initiated with a Buy at Goldman Sachs
06/11/21 BMO Capital
TCR2 Therapeutics coverage transferred at BMO Capital
05/14/21 Wedbush
TCR2 Therapeutics price target lowered to $45 from $57 at Wedbush
VERU Veru
$8.70 /

-0.1 (-1.14%)

04/13/21 Jefferies
Veru initiated with a Buy at Jefferies
02/11/21 Oppenheimer
Veru price target raised to $24 from $19 at Oppenheimer
02/11/21 H.C. Wainwright
Veru price target raised to $22 from $17 at H.C. Wainwright
02/09/21 H.C. Wainwright
Veru price target raised to $17 from $12 at H.C. Wainwright
VBLT VBL Therapeutics
$2.30 /

+0.005 (+0.22%)

08/30/21 Roth Capital
Roth bullish on VBL Therapeutics as U.S. Phase 3 OVAL trial enrollment resumes
06/15/21 Roth Capital
Roth does not see material change to VBL readout timelines
06/03/21 Roth Capital
Roth Capital ups VBL Therapeutics target to $7 on OVAL primary endpoint update
05/18/21 Guggenheim
VBL Therapeutics initiated with a Buy at Guggenheim
VTRS Viatris
$13.78 /

+0.05 (+0.36%)

06/15/21 Citi
Viatris initiated with a Neutral at Citi
04/06/21 RBC Capital
Viatris transferred with an Outperform at RBC Capital
03/25/21 Piper Sandler
Piper says Biogen Tecfidera patents could change thesis, but sees unknowns
03/12/21 Piper Sandler
Viatris price target lowered to $16 from $17 at Piper Sandler
NVS Novartis
$84.33 /

-0.735 (-0.86%)

09/07/21 Wedbush
Wedbush downgrades Xoma to Neutral, cuts target to $22
07/28/21 JPMorgan
Novartis price target raised to CHF 84 from CHF 80 at JPMorgan
07/27/21 Jefferies
Point Biopharma initiated with a Hold at Jefferies
VTRS Viatris
$13.78 /

+0.05 (+0.36%)

VERU Veru
$8.70 /

-0.1 (-1.14%)

VBLT VBL Therapeutics
$2.30 /

+0.005 (+0.22%)

TMO Thermo Fisher
$558.70 /

-4.135 (-0.73%)

TCRR TCR2 Therapeutics
$16.17 /

-0.05 (-0.31%)

TAK Takeda Pharmaceutical
$17.14 /

+0.14 (+0.82%)

SYNH Syneos Health
$93.28 /

-0.43 (-0.46%)

RHHBY Roche
$46.86 /

+0.11 (+0.24%)

REGN Regeneron
$647.54 /

-3.06 (-0.47%)

PFE Pfizer
$44.70 /

-0.07 (-0.16%)

ORIC Oric Pharmaceuticals
$25.02 /

+0.22 (+0.89%)

NVS Novartis
$84.33 /

-0.735 (-0.86%)

LPTX Leap Therapeutics
$2.34 /

+0.39 (+20.00%)

LLY Eli Lilly
$231.73 /

-1.94 (-0.83%)

IDYA Ideaya Biosciences
$25.87 /

-0.13 (-0.50%)

GSK GlaxoSmithKline
$38.92 /

-0.29 (-0.74%)

GILD Gilead
$71.34 /

-0.43 (-0.60%)

GH Guardant Health
$126.36 /

-0.65 (-0.51%)

EXAS Exact Sciences
$102.18 /

-2.46 (-2.35%)

DCPH Deciphera
$30.40 /

-0.65 (-2.09%)

CALA Calithera Biosciences
$2.06 /

-0.03 (-1.44%)

BYSI BeyondSpring
$22.25 /

-0.73 (-3.18%)

BMY Bristol-Myers
$61.18 /

-0.82 (-1.32%)

BGNE BeiGene
$377.63 /

+3.31 (+0.88%)

AYLA Ayala Pharmaceuticals
$14.30 /

+0.28 (+2.00%)

ABBV AbbVie
$107.05 /

-0.74 (-0.69%)

  • 08
    Jul
  • 03
    Jun
  • 04
    May
  • 09
    Apr
  • 01
    Mar
  • 18
    Feb
  • 20
    Jan
  • 02
    Dec
  • 02
    Dec
  • 19
    Nov
  • 13
    Nov
  • 07
    Oct
TMO Thermo Fisher
$558.70 /

-4.135 (-0.73%)

TAK Takeda Pharmaceutical
$17.14 /

+0.14 (+0.82%)

SYNH Syneos Health
$93.28 /

-0.43 (-0.46%)

RHHBY Roche
$46.86 /

+0.11 (+0.24%)

REGN Regeneron
$647.54 /

-3.06 (-0.47%)

PFE Pfizer
$44.70 /

-0.07 (-0.16%)

NVS Novartis
$84.33 /

-0.735 (-0.86%)

LLY Eli Lilly
$231.73 /

-1.94 (-0.83%)

GSK GlaxoSmithKline
$38.92 /

-0.29 (-0.74%)

GILD Gilead
$71.34 /

-0.43 (-0.60%)

EXAS Exact Sciences
$102.18 /

-2.46 (-2.35%)

BMY Bristol-Myers
$61.18 /

-0.82 (-1.32%)

BGNE BeiGene
$377.63 /

+3.31 (+0.88%)

ABBV AbbVie
$107.05 /

-0.74 (-0.69%)

VERU Veru
$8.70 /

-0.1 (-1.14%)

TMO Thermo Fisher
$558.70 /

-4.135 (-0.73%)

TAK Takeda Pharmaceutical
$17.14 /

+0.14 (+0.82%)

RHHBY Roche
$46.86 /

+0.11 (+0.24%)

REGN Regeneron
$647.54 /

-3.06 (-0.47%)

PFE Pfizer
$44.70 /

-0.07 (-0.16%)

ORIC Oric Pharmaceuticals
$25.02 /

+0.22 (+0.89%)

NVS Novartis
$84.33 /

-0.735 (-0.86%)

LPTX Leap Therapeutics
$2.34 /

+0.39 (+20.00%)

LLY Eli Lilly
$231.73 /

-1.94 (-0.83%)

IDYA Ideaya Biosciences
$25.87 /

-0.13 (-0.50%)

GSK GlaxoSmithKline
$38.92 /

-0.29 (-0.74%)

GMAB Genmab
$42.26 /

-0.57 (-1.33%)

GILD Gilead
$71.34 /

-0.43 (-0.60%)

GH Guardant Health
$126.36 /

-0.65 (-0.51%)

EXAS Exact Sciences
$102.18 /

-2.46 (-2.35%)

BYSI BeyondSpring
$22.25 /

-0.73 (-3.18%)

BMY Bristol-Myers
$61.18 /

-0.82 (-1.32%)

ABBV AbbVie
$107.05 /

-0.74 (-0.69%)

VTRS Viatris
$13.78 /

+0.05 (+0.36%)

VERU Veru
$8.70 /

-0.1 (-1.14%)

TAK Takeda Pharmaceutical
$17.14 /

+0.14 (+0.82%)

REGN Regeneron
$647.54 /

-3.06 (-0.47%)

PFE Pfizer
$44.70 /

-0.07 (-0.16%)

LLY Eli Lilly
$231.73 /

-1.94 (-0.83%)

GSK GlaxoSmithKline
$38.92 /

-0.29 (-0.74%)

GILD Gilead
$71.34 /

-0.43 (-0.60%)

BYSI BeyondSpring
$22.25 /

-0.73 (-3.18%)

BMY Bristol-Myers
$61.18 /

-0.82 (-1.32%)

ABBV AbbVie
$107.05 /

-0.74 (-0.69%)

Wednesday
Hot Stocks
Eli Lilly to supply 388,000 doses of etesevimab to U.S. government » 06:49
09/15/21
09/15
06:49
09/15/21
06:49
LLY

Eli Lilly

$233.01 /

-4.945 (-2.08%)

Eli Lilly announced an…

Eli Lilly announced an additional purchase by the U.S. government for its neutralizing antibody therapies authorized for emergency use as a treatment for COVID-19. As part of the agreement, Lilly will supply 388,000 doses of etesevimab to complement doses of bamlanivimab previously purchased by the U.S. government, with approximately 200,000 doses expected to ship Q3 and the remaining to be shipped in Q4. This transaction is expected to generate approximately $330M in revenue in the second half of 2021.

ShowHide Related Items >><<
LLY Eli Lilly
$233.01 /

-4.945 (-2.08%)

LLY Eli Lilly
$233.01 /

-4.945 (-2.08%)

09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
09/02/21 SVB Leerink
AbbVie price target lowered to $142 from $148 at SVB Leerink
08/30/21 Cowen
Eli Lilly price target raised to $300 from $250 at Cowen
08/30/21 Citi
Lexicon price target raised to $20 from $13 at Citi
LLY Eli Lilly
$233.01 /

-4.945 (-2.08%)

LLY Eli Lilly
$233.01 /

-4.945 (-2.08%)

LLY Eli Lilly
$233.01 /

-4.945 (-2.08%)

LLY Eli Lilly
$233.01 /

-4.945 (-2.08%)

Over a week ago
Hot Stocks
Thermo Fisher's Oncomine Dx Target Test receives approval by Japan MHLW » 08:12
09/10/21
09/10
08:12
09/10/21
08:12
TMO

Thermo Fisher

$568.59 /

-3.34 (-0.58%)

, LLY

Eli Lilly

$240.00 /

-14.81 (-5.81%)

Thermo Fisher Scientific…

Thermo Fisher Scientific (TMO) announced the Japan Ministry of Health, Labour and Welfare, or MHLW, Japan's regulatory agency, has granted approval for the Oncomine Dx Target Test as a next-generation sequencing-based companion diagnostic for patients with RET-fusion positive non-small-cell lung cancer who may be treated with Eli Lilly and Company's (LLY) selpercatinib. The MHLW granted orphan drug designation for selpercatinib, a tyrosine kinase inhibitor that selectively binds to the RET receptor, in 2020. "This approval will help patients suffering from non-small cell lung cancers whose tumors are positive for fusions in the RET receptor, providing access to new, potentially more effective treatments," said Hiroo Murota, vice president and general manager, Thermo Fisher Scientific Japan. "We will continue to advance precision medicine by expanding our companion diagnostic tests that identify biomarkers associated with targeted therapies." Thermo Fisher's Oncomine Dx Target Test now has approvals in Japan for five biomarkers with a total of ten associated targeted therapies for NSCLC patients.

ShowHide Related Items >><<
TMO Thermo Fisher
$568.59 /

-3.34 (-0.58%)

LLY Eli Lilly
$240.00 /

-14.81 (-5.81%)

TMO Thermo Fisher
$568.59 /

-3.34 (-0.58%)

08/04/21 Credit Suisse
Thermo Fisher assumed with an Outperform at Credit Suisse
08/04/21 Argus
Thermo Fisher price target raised to $600 from $530 at Argus
07/29/21 Cowen
Thermo Fisher price target raised to $560 from $525 at Cowen
07/29/21 BTIG
Thermo Fisher price target raised to $610 from $590 at BTIG
LLY Eli Lilly
$240.00 /

-14.81 (-5.81%)

09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
09/02/21 SVB Leerink
AbbVie price target lowered to $142 from $148 at SVB Leerink
08/30/21 Cowen
Eli Lilly price target raised to $300 from $250 at Cowen
08/30/21 Citi
Lexicon price target raised to $20 from $13 at Citi
TMO Thermo Fisher
$568.59 /

-3.34 (-0.58%)

LLY Eli Lilly
$240.00 /

-14.81 (-5.81%)

TMO Thermo Fisher
$568.59 /

-3.34 (-0.58%)

LLY Eli Lilly
$240.00 /

-14.81 (-5.81%)

TMO Thermo Fisher
$568.59 /

-3.34 (-0.58%)

LLY Eli Lilly
$240.00 /

-14.81 (-5.81%)

LLY Eli Lilly
$240.00 /

-14.81 (-5.81%)

Recommendations
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital » 14:52
09/09/21
09/09
14:52
09/09/21
14:52
JNJ

Johnson & Johnson

$168.40 /

-3.48 (-2.02%)

, LLY

Eli Lilly

$240.62 /

-14.19 (-5.57%)

, MRK

Merck

$73.71 /

-1.64 (-2.18%)

, PFE

Pfizer

$45.92 /

-0.59 (-1.27%)

, SNY

Sanofi

$49.27 /

-0.82 (-1.64%)

, AZN

AstraZeneca

$56.22 /

-0.845 (-1.48%)

, GSK

GlaxoSmithKline

$39.80 /

-0.72 (-1.78%)

, NVS

Novartis

$86.57 /

-1.005 (-1.15%)

, RHHBY

Roche

$48.49 /

-0.7 (-1.42%)

, BMY

Bristol-Myers

$63.55 /

-1.36 (-2.10%)

, INCY

Incyte

$73.25 /

-0.71 (-0.96%)

, GILD

Gilead

$70.74 /

-1.15 (-1.60%)

After HHS released the…

After HHS released the Biden administration's drug pricing plan ahead of a speech this evening from the President, RBC Capital analyst Brian Abrahams said the report's "guiding principles" were "more big-picture and contained many of the same concepts as in the prior administration's blueprint." While the plan, which Abrahams sees as likely contributing to "today's big pharma/large cap biotech weakness," reiterated "legitimate rationale" for reducing excesses and improving efficiencies in the drug industry, he sees little concrete detail on how to effectively operationalize the plan or realistically bring policymakers to agreement to actually implement it, the analyst stated. In his note, Abrahams points out specific potential implications for Incyte's (INCY) Jakafi and Gilead's (GILD) HIV drugs. Other publicly traded pharmaceutical companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).

ShowHide Related Items >><<
SNY Sanofi
$49.27 /

-0.82 (-1.64%)

RHHBY Roche
$48.49 /

-0.7 (-1.42%)

PFE Pfizer
$45.92 /

-0.59 (-1.27%)

NVS Novartis
$86.57 /

-1.005 (-1.15%)

MRK Merck
$73.71 /

-1.64 (-2.18%)

LLY Eli Lilly
$240.62 /

-14.19 (-5.57%)

JNJ Johnson & Johnson
$168.40 /

-3.48 (-2.02%)

INCY Incyte
$73.25 /

-0.71 (-0.96%)

GSK GlaxoSmithKline
$39.80 /

-0.72 (-1.78%)

GILD Gilead
$70.74 /

-1.15 (-1.60%)

BMY Bristol-Myers
$63.55 /

-1.36 (-2.10%)

AZN AstraZeneca
$56.22 /

-0.845 (-1.48%)

JNJ Johnson & Johnson
$168.40 /

-3.48 (-2.02%)

09/07/21
Fly Intel: Top five analyst downgrades
09/07/21 Morgan Stanley
Morgan Stanley downgrades J&J to Equal Weight amid limited mid-term newsflow
09/07/21 Morgan Stanley
Johnson & Johnson downgraded to Equal Weight from Overweight at Morgan Stanley
08/20/21 Morgan Stanley
J&J CEO change 'a surprise,' but not due to business issues, says Morgan Stanley
LLY Eli Lilly
$240.62 /

-14.19 (-5.57%)

09/02/21 SVB Leerink
AbbVie price target lowered to $142 from $148 at SVB Leerink
08/30/21 Cowen
Eli Lilly price target raised to $300 from $250 at Cowen
08/30/21 Citi
Lexicon price target raised to $20 from $13 at Citi
08/09/21 Argus
Eli Lilly price target raised to $300 from $225 at Argus
MRK Merck
$73.71 /

-1.64 (-2.18%)

09/07/21 Morgan Stanley
Morgan Stanley downgrades Merck to Equal Weight, awaits strategic action
09/07/21 Morgan Stanley
Merck downgraded to Equal Weight from Overweight at Morgan Stanley
08/25/21 H.C. Wainwright
Ligand gets royalty on sales of Merck's Vaxneuvance, says H.C. Wainwright
PFE Pfizer
$45.92 /

-0.59 (-1.27%)

09/07/21 Jefferies
Celcuity initiated with a Buy, $48 price target at Jefferies
09/01/21 Mizuho
FDA JAK safety update not great 'but AbbVie selloff overdone, says Mizuho
09/01/21 Piper Sandler
AbbVie should be bought on label change selloff, says Piper Sandler
SNY Sanofi
$49.27 /

-0.82 (-1.64%)

09/09/21 Benchmark
Sanofi deal for Kadmon reinforces Incyte thesis, says Benchmark
09/01/21 Piper Sandler
Piper Sandler ups Connect Biopharma target to $31 after results, pipeline update
08/12/21 UBS
Sanofi price target lowered to EUR 100 from EUR 101 at UBS
08/06/21 Morgan Stanley
Sanofi price target raised to EUR 106 from EUR 104 at Morgan Stanley
AZN AstraZeneca
$56.22 /

-0.845 (-1.48%)

08/12/21 JPMorgan
AstraZeneca resumed with an Overweight at JPMorgan
08/11/21 Goldman Sachs
FibroGen price target lowered to $16 from $22 at Goldman Sachs
08/09/21 Morgan Stanley
AstraZeneca resumed with an Overweight at Morgan Stanley
08/04/21 SVB Leerink
AstraZeneca price target raised to $69 from $63 at SVB Leerink
GSK GlaxoSmithKline
$39.80 /

-0.72 (-1.78%)

08/26/21 UBS
GlaxoSmithKline price target raised to 1,540 GBp from 1,485 GBp at UBS
08/20/21 JPMorgan
GlaxoSmithKline price target raised to 1,500 GBp from 1,300 GBp at JPMorgan
08/19/21 Berenberg
GlaxoSmithKline price target raised to 1,625 GBp from 1,570 GBp at Berenberg
08/18/21 Wedbush
AnaptysBio price target raised to $25 from $20 at Wedbush
NVS Novartis
$86.57 /

-1.005 (-1.15%)

09/07/21 Wedbush
Wedbush downgrades Xoma to Neutral, cuts target to $22
07/28/21 JPMorgan
Novartis price target raised to CHF 84 from CHF 80 at JPMorgan
07/27/21 Jefferies
Point Biopharma initiated with a Hold at Jefferies
07/22/21 Deutsche Bank
Novartis downgraded to Hold from Buy at Deutsche Bank
RHHBY Roche
$48.49 /

-0.7 (-1.42%)

09/07/21 UBS
Roche price target raised to CHF 350 from CHF 345 at UBS
08/02/21 JPMorgan
Roche price target raised to CHF 360 from CHF 310 at JPMorgan
07/27/21 Societe Generale
Roche price target raised to CHF 353 from CHF 340 at Societe Generale
07/23/21 Barclays
Roche price target raised to CHF 395 from CHF 375 at Barclays
BMY Bristol-Myers
$63.55 /

-1.36 (-2.10%)

07/27/21 Mizuho
Bristol-Myers deal a positive signal about BridgeBio's BBP-398, says Mizuho
07/26/21 Truist
Bristol-Myers assumed with a Buy at Truist
07/26/21 Truist
Bristol-Myers assumed with a Buy at Truist
07/19/21 JMP Securities
Cytokinetics price target raised to $44 from $26 at JMP Securities
INCY Incyte
$73.25 /

-0.71 (-0.96%)

09/01/21 Cowen
Odds of Incyte drug exclusion from class warning 'largely unchanged,' says Cowen
07/20/21 Benchmark
Incyte upgraded to Buy from Hold at Benchmark
06/25/21 RBC Capital
Incyte price target lowered to $88 from $92 at RBC Capital
GILD Gilead
$70.74 /

-1.15 (-1.60%)

07/30/21 BMO Capital
Gilead price target raised to $72 from $67 at BMO Capital
07/30/21 RBC Capital
Gilead price target raised to $84 from $81 at RBC Capital
06/29/21 Jefferies
Gilead data should move Yescarta up to second line in DLBCL, says Jefferies
06/16/21 Roth Capital
JTX-1811 IND-clearance further validates Jounce platform, says Roth Capital
SNY Sanofi
$49.27 /

-0.82 (-1.64%)

RHHBY Roche
$48.49 /

-0.7 (-1.42%)

PFE Pfizer
$45.92 /

-0.59 (-1.27%)

NVS Novartis
$86.57 /

-1.005 (-1.15%)

MRK Merck
$73.71 /

-1.64 (-2.18%)

LLY Eli Lilly
$240.62 /

-14.19 (-5.57%)

JNJ Johnson & Johnson
$168.40 /

-3.48 (-2.02%)

INCY Incyte
$73.25 /

-0.71 (-0.96%)

GSK GlaxoSmithKline
$39.80 /

-0.72 (-1.78%)

GILD Gilead
$70.74 /

-1.15 (-1.60%)

BMY Bristol-Myers
$63.55 /

-1.36 (-2.10%)

AZN AstraZeneca
$56.22 /

-0.845 (-1.48%)

SNY Sanofi
$49.27 /

-0.82 (-1.64%)

RHHBY Roche
$48.49 /

-0.7 (-1.42%)

PFE Pfizer
$45.92 /

-0.59 (-1.27%)

NVS Novartis
$86.57 /

-1.005 (-1.15%)

MRK Merck
$73.71 /

-1.64 (-2.18%)

LLY Eli Lilly
$240.62 /

-14.19 (-5.57%)

JNJ Johnson & Johnson
$168.40 /

-3.48 (-2.02%)

INCY Incyte
$73.25 /

-0.71 (-0.96%)

GSK GlaxoSmithKline
$39.80 /

-0.72 (-1.78%)

GILD Gilead
$70.74 /

-1.15 (-1.60%)

BMY Bristol-Myers
$63.55 /

-1.36 (-2.10%)

AZN AstraZeneca
$56.22 /

-0.845 (-1.48%)

SNY Sanofi
$49.27 /

-0.82 (-1.64%)

RHHBY Roche
$48.49 /

-0.7 (-1.42%)

PFE Pfizer
$45.92 /

-0.59 (-1.27%)

NVS Novartis
$86.57 /

-1.005 (-1.15%)

MRK Merck
$73.71 /

-1.64 (-2.18%)

LLY Eli Lilly
$240.62 /

-14.19 (-5.57%)

JNJ Johnson & Johnson
$168.40 /

-3.48 (-2.02%)

GSK GlaxoSmithKline
$39.80 /

-0.72 (-1.78%)

GILD Gilead
$70.74 /

-1.15 (-1.60%)

BMY Bristol-Myers
$63.55 /

-1.36 (-2.10%)

AZN AstraZeneca
$56.22 /

-0.845 (-1.48%)

PFE Pfizer
$45.92 /

-0.59 (-1.27%)

MRK Merck
$73.71 /

-1.64 (-2.18%)

LLY Eli Lilly
$240.62 /

-14.19 (-5.57%)

JNJ Johnson & Johnson
$168.40 /

-3.48 (-2.02%)

INCY Incyte
$73.25 /

-0.71 (-0.96%)

GSK GlaxoSmithKline
$39.80 /

-0.72 (-1.78%)

GILD Gilead
$70.74 /

-1.15 (-1.60%)

BMY Bristol-Myers
$63.55 /

-1.36 (-2.10%)

AZN AstraZeneca
$56.22 /

-0.845 (-1.48%)

Hot Stocks
HHS Secretary releases proposal to lower prescription drug costs » 14:41
09/09/21
09/09
14:41
09/09/21
14:41
AZN

AstraZeneca

$56.22 /

-0.84 (-1.47%)

, BMY

Bristol-Myers

$63.59 /

-1.32 (-2.03%)

, LLY

Eli Lilly

$240.92 /

-13.89 (-5.45%)

, GSK

GlaxoSmithKline

$39.81 /

-0.71 (-1.75%)

, JNJ

Johnson & Johnson

$168.53 /

-3.35 (-1.95%)

, MRK

Merck

$73.71 /

-1.64 (-2.18%)

, NVS

Novartis

$86.64 /

-0.935 (-1.07%)

, PFE

Pfizer

$45.93 /

-0.58 (-1.25%)

, RHHBY

Roche

$48.49 /

-0.7 (-1.42%)

, SNY

Sanofi

$49.23 /

-0.86 (-1.72%)

Health and Human Services…

Health and Human Services Secretary Xavier Becerra has released a comprehensive plan to lower drug prices. The Drug Pricing Plan is part of a broader initiative stemming from President Joe Biden's Executive Order on Promoting Competition in the American Economy, which also created the White House Competition Council tasked with coordinating, promoting, and advancing Federal Government efforts to address overconcentration, monopolization, and unfair competition in or directly affecting the American economy. "Americans pay too much for prescription drugs - more than $1,500 per person - and pay prices that are far higher than any comparable nation. Prices for brand name drugs are rising faster than inflation. Many Americans do not take medications as prescribed because of their cost, with resulting harm to their health care and health. Lack of competition is a key factor in these high drug costs," the HHS' statement reads. The Drug Pricing Plan responds to the request in President Biden's Executive Order for "a plan to continue the effort to combat excessive pricing of prescription drugs and enhance domestic pharmaceutical supply chains, to reduce the prices paid by the Federal Government for such drugs, and to address the recurrent problem of price gouging." One of the key policies in this effort is legislation that would allow the Secretary of HHS to negotiate Medicare Part B and Part D drug prices directly with pharmaceutical companies and make those prices available to other purchasers, an approach that is projected to generate reductions in patient cost-sharing and large savings for patients, government, and commercial payers. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).Reference Link

ShowHide Related Items >><<
SNY Sanofi
$49.23 /

-0.86 (-1.72%)

RHHBY Roche
$48.49 /

-0.7 (-1.42%)

PFE Pfizer
$45.93 /

-0.58 (-1.25%)

NVS Novartis
$86.64 /

-0.935 (-1.07%)

MRK Merck
$73.71 /

-1.64 (-2.18%)

LLY Eli Lilly
$240.92 /

-13.89 (-5.45%)

JNJ Johnson & Johnson
$168.53 /

-3.35 (-1.95%)

GSK GlaxoSmithKline
$39.81 /

-0.71 (-1.75%)

BMY Bristol-Myers
$63.59 /

-1.32 (-2.03%)

AZN AstraZeneca
$56.22 /

-0.84 (-1.47%)

AZN AstraZeneca
$56.22 /

-0.84 (-1.47%)

08/12/21 JPMorgan
AstraZeneca resumed with an Overweight at JPMorgan
08/11/21 Goldman Sachs
FibroGen price target lowered to $16 from $22 at Goldman Sachs
08/09/21 Morgan Stanley
AstraZeneca resumed with an Overweight at Morgan Stanley
08/04/21 SVB Leerink
AstraZeneca price target raised to $69 from $63 at SVB Leerink
BMY Bristol-Myers
$63.59 /

-1.32 (-2.03%)

07/27/21 Mizuho
Bristol-Myers deal a positive signal about BridgeBio's BBP-398, says Mizuho
07/26/21 Truist
Bristol-Myers assumed with a Buy at Truist
07/26/21 Truist
Bristol-Myers assumed with a Buy at Truist
07/19/21 JMP Securities
Cytokinetics price target raised to $44 from $26 at JMP Securities
LLY Eli Lilly
$240.92 /

-13.89 (-5.45%)

09/02/21 SVB Leerink
AbbVie price target lowered to $142 from $148 at SVB Leerink
08/30/21 Cowen
Eli Lilly price target raised to $300 from $250 at Cowen
08/30/21 Citi
Lexicon price target raised to $20 from $13 at Citi
08/09/21 Argus
Eli Lilly price target raised to $300 from $225 at Argus
GSK GlaxoSmithKline
$39.81 /

-0.71 (-1.75%)

08/26/21 UBS
GlaxoSmithKline price target raised to 1,540 GBp from 1,485 GBp at UBS
08/20/21 JPMorgan
GlaxoSmithKline price target raised to 1,500 GBp from 1,300 GBp at JPMorgan
08/19/21 Berenberg
GlaxoSmithKline price target raised to 1,625 GBp from 1,570 GBp at Berenberg
08/18/21 Wedbush
AnaptysBio price target raised to $25 from $20 at Wedbush
JNJ Johnson & Johnson
$168.53 /

-3.35 (-1.95%)

09/07/21
Fly Intel: Top five analyst downgrades
09/07/21 Morgan Stanley
Morgan Stanley downgrades J&J to Equal Weight amid limited mid-term newsflow
09/07/21 Morgan Stanley
Johnson & Johnson downgraded to Equal Weight from Overweight at Morgan Stanley
08/20/21 Morgan Stanley
J&J CEO change 'a surprise,' but not due to business issues, says Morgan Stanley
MRK Merck
$73.71 /

-1.64 (-2.18%)

09/07/21 Morgan Stanley
Morgan Stanley downgrades Merck to Equal Weight, awaits strategic action
09/07/21 Morgan Stanley
Merck downgraded to Equal Weight from Overweight at Morgan Stanley
08/25/21 H.C. Wainwright
Ligand gets royalty on sales of Merck's Vaxneuvance, says H.C. Wainwright
NVS Novartis
$86.64 /

-0.935 (-1.07%)

09/07/21 Wedbush
Wedbush downgrades Xoma to Neutral, cuts target to $22
07/28/21 JPMorgan
Novartis price target raised to CHF 84 from CHF 80 at JPMorgan
07/27/21 Jefferies
Point Biopharma initiated with a Hold at Jefferies
07/22/21 Deutsche Bank
Novartis downgraded to Hold from Buy at Deutsche Bank
PFE Pfizer
$45.93 /

-0.58 (-1.25%)

09/07/21 Jefferies
Celcuity initiated with a Buy, $48 price target at Jefferies
09/01/21 Mizuho
FDA JAK safety update not great 'but AbbVie selloff overdone, says Mizuho
09/01/21 Piper Sandler
AbbVie should be bought on label change selloff, says Piper Sandler
RHHBY Roche
$48.49 /

-0.7 (-1.42%)

09/07/21 UBS
Roche price target raised to CHF 350 from CHF 345 at UBS
08/02/21 JPMorgan
Roche price target raised to CHF 360 from CHF 310 at JPMorgan
07/27/21 Societe Generale
Roche price target raised to CHF 353 from CHF 340 at Societe Generale
07/23/21 Barclays
Roche price target raised to CHF 395 from CHF 375 at Barclays
SNY Sanofi
$49.23 /

-0.86 (-1.72%)

09/09/21 Benchmark
Sanofi deal for Kadmon reinforces Incyte thesis, says Benchmark
09/01/21 Piper Sandler
Piper Sandler ups Connect Biopharma target to $31 after results, pipeline update
08/12/21 UBS
Sanofi price target lowered to EUR 100 from EUR 101 at UBS
08/06/21 Morgan Stanley
Sanofi price target raised to EUR 106 from EUR 104 at Morgan Stanley
SNY Sanofi
$49.23 /

-0.86 (-1.72%)

RHHBY Roche
$48.49 /

-0.7 (-1.42%)

PFE Pfizer
$45.93 /

-0.58 (-1.25%)

NVS Novartis
$86.64 /

-0.935 (-1.07%)

MRK Merck
$73.71 /

-1.64 (-2.18%)

LLY Eli Lilly
$240.92 /

-13.89 (-5.45%)

JNJ Johnson & Johnson
$168.53 /

-3.35 (-1.95%)

GSK GlaxoSmithKline
$39.81 /

-0.71 (-1.75%)

BMY Bristol-Myers
$63.59 /

-1.32 (-2.03%)

AZN AstraZeneca
$56.22 /

-0.84 (-1.47%)

SNY Sanofi
$49.23 /

-0.86 (-1.72%)

RHHBY Roche
$48.49 /

-0.7 (-1.42%)

PFE Pfizer
$45.93 /

-0.58 (-1.25%)

NVS Novartis
$86.64 /

-0.935 (-1.07%)

MRK Merck
$73.71 /

-1.64 (-2.18%)

LLY Eli Lilly
$240.92 /

-13.89 (-5.45%)

JNJ Johnson & Johnson
$168.53 /

-3.35 (-1.95%)

GSK GlaxoSmithKline
$39.81 /

-0.71 (-1.75%)

BMY Bristol-Myers
$63.59 /

-1.32 (-2.03%)

AZN AstraZeneca
$56.22 /

-0.84 (-1.47%)

SNY Sanofi
$49.23 /

-0.86 (-1.72%)

RHHBY Roche
$48.49 /

-0.7 (-1.42%)

PFE Pfizer
$45.93 /

-0.58 (-1.25%)

NVS Novartis
$86.64 /

-0.935 (-1.07%)

MRK Merck
$73.71 /

-1.64 (-2.18%)

LLY Eli Lilly
$240.92 /

-13.89 (-5.45%)

JNJ Johnson & Johnson
$168.53 /

-3.35 (-1.95%)

GSK GlaxoSmithKline
$39.81 /

-0.71 (-1.75%)

BMY Bristol-Myers
$63.59 /

-1.32 (-2.03%)

AZN AstraZeneca
$56.22 /

-0.84 (-1.47%)

PFE Pfizer
$45.93 /

-0.58 (-1.25%)

MRK Merck
$73.71 /

-1.64 (-2.18%)

LLY Eli Lilly
$240.92 /

-13.89 (-5.45%)

JNJ Johnson & Johnson
$168.53 /

-3.35 (-1.95%)

GSK GlaxoSmithKline
$39.81 /

-0.71 (-1.75%)

BMY Bristol-Myers
$63.59 /

-1.32 (-2.03%)

AZN AstraZeneca
$56.22 /

-0.84 (-1.47%)

Hot Stocks
Eli Lilly announce Jardiance granted breakthrough therapy design by FDA » 08:09
09/09/21
09/09
08:09
09/09/21
08:09
LLY

Eli Lilly

$254.81 /

+0.01 (+0.00%)

The U.S. Food and Drug…

The U.S. Food and Drug Administration granted Breakthrough Therapy designation for Jardiance as an investigational treatment for adults with heart failure with preserved ejection fraction, Boehringer Ingelheim and Eli Lilly announced. The decision is based on results from the landmark EMPEROR-Preserved phase III trial, in which Jardiance demonstrated a 21% relative risk reduction for the composite primary endpoint of cardiovascular death or hospitalization for heart failure in adults with heart failure with preserved ejection fraction compared with placebo. "This Breakthrough Therapy designation underscores the potential of Jardiance to help fill a critical need for a clinically proven treatment for people with this highly prevalent, difficult-to-treat condition," said Mohamed Eid, M.D., M.P.H., M.H.A., vice president, Clinical Development & Medical Affairs, Cardio-Metabolism & Respiratory Medicine, Boehringer Ingelheim Pharmaceuticals. "Following the recent FDA approval of Jardiance for heart failure with reduced ejection fraction, this is another important milestone supporting the potential of Jardiance as the first therapy clinically proven to improve outcomes across the full heart failure spectrum."

ShowHide Related Items >><<
LLY Eli Lilly
$254.81 /

+0.01 (+0.00%)

LLY Eli Lilly
$254.81 /

+0.01 (+0.00%)

09/02/21 SVB Leerink
AbbVie price target lowered to $142 from $148 at SVB Leerink
08/30/21 Cowen
Eli Lilly price target raised to $300 from $250 at Cowen
08/30/21 Citi
Lexicon price target raised to $20 from $13 at Citi
08/09/21 Argus
Eli Lilly price target raised to $300 from $225 at Argus
LLY Eli Lilly
$254.81 /

+0.01 (+0.00%)

LLY Eli Lilly
$254.81 /

+0.01 (+0.00%)

LLY Eli Lilly
$254.81 /

+0.01 (+0.00%)

LLY Eli Lilly
$254.81 /

+0.01 (+0.00%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.